GlaxoSmithKline receives FDA approval for new presentation of Menveo asset

Drugmaker GlaxoSmithKline has received Food and Drug Administration approval for a new presentation of its invasive meningococcal disease vaccine.

GlaxoSmithKline said on Monday that a new single-vial presentation option of its Menveo asset removes the need for reconstitution of the drug before use in individuals 10-55 years of age.

The FTSE 100-listed group noted that its original two-vial presentation of Menveo was approved by the FDA in 2010 and also remains available for use in individuals from two months to 55 years of age.

Roger Connor, GSK's president of vaccines and global health, said: "Outbreaks of this dangerous disease continue to occur, impacting families, health systems, and society. This FDA approval of Menveo one-vial presentation offers greater convenience to healthcare providers to help prevent this disease in at-risk populations in the United States."

Reporting by Iain Gilbert at Sharecast.com